Refine
Has Fulltext
- yes (53)
Is part of the Bibliography
- yes (53)
Year of publication
Document Type
- Journal article (39)
- Doctoral Thesis (11)
- Report (2)
- Review (1)
Keywords
- Neurobiologie (53) (remove)
Institute
- Neurochirurgische Klinik und Poliklinik (41)
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Graduate School of Life Sciences (4)
- Institut für Klinische Neurobiologie (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Medizinische Klinik (bis 2004) (1)
- Physiologisches Institut (1)
- Rudolf-Virchow-Zentrum (1)
Thyrotropin-releasing hormonewas shown to exert potent ventilatory effects after centrat administration. These data, however, were derived from studies using anesthetized animal preparations. Since TRH elicits strong arousal reactions, the observed ventilatory effects of TRH under anesthesia may have been due to nonspecific reduction in the anesthetic state of the animals. In order to clarify the extent to which the reversal of anesthesia may change ventilatory parameters after TRH application, we investigated the effect of TRH on Ventilation rate, relative tidal volume, relative respiratory minute volume, CO\(_2\) production CO\(_2\) consumption, and locomotor activity in the conscious, unrestrained rat. Intracerebroventricular application of TRH induced a dose-dependent, sustained increase in ventilation rate, relative tidal volume, and relative respiratory minute volume of maximally 128%, 890%, and 235%, respectively. In addition, CO\(_2\) production and O\(_2\) consumption were elevated by 4.6 and 11.7 fold, whiJe no significant changes in locomotor activity were observed. The results suggest that TRH stimulates ventilation by a mechanism independent of its analeptic properties.
In einer vorangegangenen Arbeit konnte eine hypomorphe Mutation innerhalb des Genlokus einer putativen Serin-/Threonin-Kinase als Auslöser der Aggregatbildung des Aktive-Zone- Proteins Bruchpilot in larvalen Motoneuronaxonen identifiziert werden (Nieratschker, 2004). Aufgrund der Homologien dieser Kinase zu SR-Proteinkinasen wurde der Name Serin- /Threonin-Proteinkinase 3 (SRPK3) vorgeschlagen. Laut ursprünglicher Annotation der „Flybase“ (http://flybase.bio.indiana.edu) codiert der Genlokus der Srpk3, der auf dem linken Arm des dritten Chromosoms innerhalb der Region 79D4 lokalisiert ist und sich über ca. 10,3 kb erstreckt, für zwei Transkripte (Srpk3-RC und Srpk3-RB). Diese beiden Transkripte haben unterschiedliche Transkriptions- und Translationsstartpunkte und unterscheiden sich in ihrem ersten kodierenden Exon, ab dem vierten Exon sind sie allerdings identisch. Das Srpk3-RCTranskript umfasst ca. 4,2 kb, das Srpk3-RB-Transkript ca. 3,8 kb. Die von diesen Transkripten kodierten Proteine bestehen aus 816 (Srpk3-RC) bzw. 749 (Srpk3-RB) Aminosäuren. Diese beiden ursprünglich annotierten Transkripte konnten durch RT-PCR-Experimente bestätigt werden. Dabei wurde auch ein zusätzliches, alternativ gespleißtes Exon von 159 bp entdeckt, das beiden Transkripten zugeordnet werden kann. Somit codiert der Srpk3-Genlokus für mindestens vier Transkripte, die Transkripte der RC/RF-Transkriptgruppe mit (Srpk3-RF) und ohne (Srpk3-RC) das alternativ gespleißte Exon und die Transkripte der RB/RETranskriptgruppe mit (Srpk3-RE) und ohne (Srpk3-RB) das alternativ gespleißte Exon. Die Existenz eines weiteren Transkriptes Srpk3-RD, die in der aktuellen Version der „Flybase“ annotiert ist, konnte durch RT-PCR-Experimente nicht nachgewiesen werden. Zu Beginn dieser Arbeit lag eine hypomorphe Mutante für die SRPK3 schon vor (Srpk3P1; Eberle, 1995). Diese Linie trägt eine P-Elementinsertion innerhalb des ersten Exons der RC/RF-Transkriptgruppe, die das Leseraster dieser Transkriptgruppe zerstört, so dass in dieser Linie nur die RB/RE-Transkriptgruppe gebildet werden kann. Wie bereits erwähnt, konnte diese Mutation in vorangegangenen Arbeiten bereits als der Auslöser der Aggregatbildung des Bruchpilot-Proteins in larvalen Motoneuronaxone, sowie einiger Verhaltensdefekte identifiziert werden (Nieratschker, 2004; Bock 2006). Diese Verhaltensdefekte ähneln stark denen, die durch einen knock-down der Bruchpilot-Expression mittels RNAi ausgelöst werden (Wagh et al., 2006; Bock, 2006), was auf eine Interaktion beider Proteine schließen lässt. Um nun den Beweis führen zu können, dass tatsächlich diese Mutation die beobachteten Phänotypen verursacht, wurden Rettungsversuche durchgeführt. Die Srpk3-RF-cDNA war dabei in der Lage die durch die hypomorphe Mutation der SRPK3 verursachten Phänotypen vollständig, oder zumindest teilweise zu retten (vgl. auch Bock, 2006; Bloch, 2007). Damit konnte belegt werden, dass die hypomorphe Mutation der SRPK3 tatsächlich die in der Mutante Srpk3P1 beobachteten Phänotypen verursacht. Um die durch in situ Hybridisierung erhaltenen Daten zur Lokalisation der SRPK3 im larvalen Gehirn (Nieratschker, 2004) bestätigen, sowie weitere Daten erhalten zu können, wurden Isoform-spezifische Antisera gegen die SRPK3 generiert. Diese Antiseren sind in der Lage überexprimiertes Protein zu detektieren (Bloch, 2007), allerdings ist es mit diesen Antiseren nicht möglich die SRPK3 in wildtypischen Präparaten nachzuweisen. Weitere Daten zur Lokalisation der SRPK3, die durch die Verwendung eines SRPK3-eGFPFusionsproteins erhalten wurden, zeigten, dass eine der ektopisch überexprimierten SRPK3- Isoformen mit Bruchpilot an der Aktiven Zone kolokalisiert. Dieses Ergebnis, in Verbindung mit den durch die Mutation der SRPK3 verursachten Bruchpilot-Aggregaten in larvalen Motoneuronaxonen und den Verhaltensdefekten, gibt Hinweise auf eine mögliche direkte Interaktion beider Proteine….
In this thesis I studied psychological aspects in the behaviour of Drosophila, and especially Drosophila larvae. After an introduction where I present the general scientific context and describe the mechanisms of olfactory perception as well as of classical and operant conditioning, I present the different experiments that I realised during my PhD. Perception The second chapter deals with the way adult Drosophila generalise between single odours and binary mixtures of odours. I found that flies perceive a mixture of two odours as equally similar to the two elements composing it; and that the intensity as well as the physico-chemical nature of the elements composing a mixture affect the degree of generalisation between this mixture and one of its elements. These findings now call for further investigation on the physiological level, using functional imaging. Memory The third chapter presents a series of experiments in Drosophila larvae in order to define some characteristics of a new protocol for classical aversive learning which involves associating odours with mechanical disturbance as a punishment. The protocol and the first results should open new doors for the study of classical conditioning in Drosophila larvae, by allowing the comparison between two types of aversive memory (gustatory vs. mechanical reinforcement), including a comparison of their neurogenetic bases. It will also allow enquiries into the question whether these respective memories are specific for the kind of reinforcer used. Agency The fourth chapter documents our attempts to establish operant memory in Drosophila larvae. By analysing the first moments of the test, I could reveal that the larvae modified their behaviour according to their previous operant training. However, this memory seems to be quickly extinguished during the course of the test. We now aim at repeating these results and improving the protocol, in order to be able to systematically study the mechanisms allowing and underlying operant learning in Drosophila larvae. In the fifth chapter, I use the methods developed in chapter four for an analysis of larval locomotion. I determine whether larval locomotion in terms of speed or angular speed is affected by a treatment with the “cognitive enhancer” Rhodiola rosea, or by mutations in the Synapsin or SAP47 genes which are involved in the formation of olfactory memory. I also characterize the modifications induced by the presence of gustatory stimuli in the substrate on which the larvae are crawling. This thesis thus brings new elements to the current knowledge of Drosophila
The amounts of tissue factor (TF) expressed by brain microvascular endothelial cells (BMECs) from normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were compared after stimulating the cells with different doses of lipopolysaccharide (LPS), thrombin, phorbol myristic acid (PMA), Ca\(^{2+}\)·ionophore (A23187), or tumor necrosis factor (TNF) and interleukin·l (IL.l). Treatment ofcultured BMECs fron. WKY and SHR with all of these factors dose·dependently increased their total amount of TF; no substantive differences in the Ieveis of enhanced TF expression were observed between WKY and SHR BMECs. We conclude that stimulated endothelium from rats with hypertension, a major stroke risk factor, is not hyperresponsive with respect to TF expression when compared to normotensive controls.
Tyr-o-Arg\(^2\)-Phe-sarcosine\(^4\) (TAPS), a mu-selective tetrapeptide analog of dermorphin, induced sustained antinociception and stimulated ventilatory minute volume (MV) at the doses of 3 to 100 pmol i.c.v. The doses of 30 and 100 pmol i.c.v. induced catalepsy. The effect of TAPS on MV was in negative correlation with the dose and the maximal response was achieved by the lowest (3 pmol) dose (+63 ± 23%, P < .05). Morphine, an agonist at both mu\(_1\) and mu\(_2\) sites, at a dose of 150 nmol i.c.v. (equianalgetic to 100 pmol of TAPS decreased the MV by 30%, due to a decrease in ventilatory tidal volume. The antinociceptive effect of TAPS was antagonized by naloxone and the mu, receptor antagonist, naloxonazine. Naloxonazine also attenuated the catalepsy produced by 1 00 pmol of TAPS i.c. v. and the respiratory Stimulation produced by 3 pmol of TAPS i.c.v. Pretreatment with 30 pmol of TAPS antagonized the respiratory depression induced by the mu opioid agonist dermorphin (changes in MV after dermorphin alone at 1 or 3 nmol were -22 ± 1 0% and -60 ± 9% and, after pretreatment with TAPS, +44 ± 11 % and -18 ± 5%, respectively). After combined pretreatment with naloxonazine and TAPS, 1 nmol of dermorphin had no significant effect on ventilation. In contrast, pretreatment with a low respiratory stimulant dose (10 pmol i.c.v.) of dermorphin did not modify the effect of 1 nmol of dermorphin. ln conclusion, the antinociceptive, cataleptic and respiratory stimulant effects of TAPS appear to be a related to its agonist action at the mu, opioid receptors. TAPS did not induce respiratory depression (a mu\(_2\) opioid effect) but antagonized the respiratory depressant effect of another mu agonist. Thus, in vivo TAPS appears to act as a mu\(_2\) receptor antagonist.
Prostag1andin F\(_{2\alpha}\) (PGF\(_{2\alpha}\)) is one of the most common metabo1ites of arachidonic acid (M) in rat brain. When administered intracerebroventricularly (i.c.v.) to rats, both AA and PGFal exert dose-related hypertensive, tachycardic and hyperthermic effects. Metabolie alterations in the endogenaus formation of some prostaglandins in the brain-stem of spontaneously hypertensive rats (SHR) have been reported. Therefore the central effects of AA and PGF \(_{2\alpha}\) on blood pressure, heart rate and body temperature were studied both in SHR and nonootensive Wistar rats (NR) under urethane-anaesthesia. The hypertensive effect of AA i.c.v. (0.01-100 \(\mu\)g/rat) was larger in magni tude in SHR than in NR, but there was no significant difference in the M-induced changes of heart rate and body temperature between the groups. Pretreatment of NR wi th soditm1 :meclofenamate (1 mg/rat i.c.v.) antagonised the central effects of M indicating that these effects are not due to M itself but to its conversion to prostaglandins. Unlike the effects of AA, the central hypertensive, tachycardic and hyperthennic responses to PGF\(_{2\alpha}\) (0.5-50 l-lg/rat i.c.v .) were significantly attenuated in SHR. The present results obtained with M are conpatible with the previous assumption that the synthesis of prostaglandins in the brain of SHR might differ from that in NR. The results also demonstrate that the central effects of PGF\(_{2\alpha}\) are reduced in SHR.
The acute effect ofT-2 toxemia on local blood flow and vascular resistance in hindquarter. mesenteric. and renal vascular beds was continuously measured by the directional pulsed Doppler technique in conscious, male Sprague-Dawley rats. Intravenous injection ofT-2 toxin (I mg/kg) in the conscious rat reduced blood flow and increased vascular resistance in all blood vessels studied but had no significant effect on mean arterial pressure or heart rate. The blood flow in hindquarters gradually decreased to a minimum of -77 ± 9% (mean ±SE) 6 hr after the toxin injection. The hindquarter vascular resistance concomitantly increased to a maximum value of + 323 ± 69% above thc resistance before toxin administration. Mesenteric and renal blood flow initially increased (slightly) and then gradually decreased. The maximum drop of blood flow, -90 ± 13% and -76 ± 13% for the mesenteric and renal vascular beds, respectively, was achieved 4 hr after T-2 toxin injection and the blood flow values remained low for up to 6 hr. Simultaneously with the impairment of
The cardiovascular and endocrine activity of three analogs of thyrotropin releasing hor.mone (TRH), 4-nitro-imidazole TRH (4-nitroTRH), 2-trifluoro-methyl-imidazole TRH (2-TFM-TRH) and 4-trifluoromethyl- imidazole TRH (4-TFM-TRH), was compared to TRH in conscious rats. Injection of TRH or the three analogs (1 mg/kg or 5 mg/kg) into the arterial line induced increases in mean arterial pressure, pulse pressure and heart rate and raised plasma prolactin (PRL). None of the analogs were more potent than TRH in inducing cardiovascular changes. The 4-TFM-TRH was significantly less potent than the 2-TFM-TRH in increasing blood pressure, while the nitro-TRH was more potent than the 2-TFM-TRH in producing tachycardia. TRH induced a two-fold increase in PRL at the 5 mg/kg dose, while both the fluorinated analogs elici ted a 4 to 5 fold increase in PRL at the higher dose. The present results suggest that the receptors for TRH-elicited PRL release differ from TRH-receptors involved in its cardiovascular actions.